Dergiler / Turkish Journal of Medical Sciences / 2016 / Cilt: 46 - Sayı: 6

The factors affecting survival in patients with bronchiectasis

Sayfa
1838–1845
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Advanced age, comorbid conditions, reduced partial oxygen pressure, pulmonary hypertension, and Pseudomonas aeruginosa proliferation in sputum increase its mortality rate.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: There is limited information about the rate and modifiers of mortality in noncystic fibrosis bronchiectasis.
📊
Temel Bulgular & Veri:Materials and methods: This study enrolled a total of 56 bronchiectasis patients.
💡
Sonuç & Katkı:Advanced age, comorbid conditions, reduced partial oxygen pressure, pulmonary hypertension, and Pseudomonas aeruginosa proliferation in sputum increase its mortality rate.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: There is limited information about the rate and modifiers of mortality in noncystic fibrosis bronchiectasis. Materials and methods: This study enrolled a total of 56 bronchiectasis patients. Patients body mass index, smoking habit, previous therapies, comorbid disorders, history of vaccination, bronchiectasis type and radiological extent, arterial blood gas analysis, respiratory function tests, and laboratory results were recorded. Results: After a follow-up of 65.38 ± 18.62 months the overall mortality rate was 35.7%. The mean survival duration was 46.42 ± 8.25 months. Advanced age significantly increased mortality (HR: 2.031; CI: 0.991 4.072, P = 0.035). A significant correlation was found between mortality rate and the partial oxygen pressure level (HR: 0.886 (CI: 0.817 0.960); P = 0.039). Pulmonary artery pressure was directly proportional to mortality rate (HR: 9.015 (CI: 3.272 94.036); P = 0.03). There was also a significant correlation between Pseudomonas aeruginosa proliferation in sputum and mortality (HR: 7.014 (CI: 2.812 17.962); P = 0.00). Comorbidities increased mortality (HR: 1.984 (CI: 0.972 2.996); P = 0.04). Conclusion: Bronchiectasis is a disease with high mortality. Advanced age, comorbid conditions, reduced partial oxygen pressure, pulmonary hypertension, and Pseudomonas aeruginosa proliferation in sputum increase its mortality rate.

🔖

Bu Makaleye Atıf Yap

ACICAN, T., ÖNEN, Z. P., ÇİFTCİ, F., YILDIZ, Ö., GÜLBAY, B., SARYAL, S. B., ŞEN, E., KARABIYIKOĞLU, G. (2022). The factors affecting survival in patients with bronchiectasis. Turkish Journal of Medical Sciences, Cilt: 46 - Sayı: 6, 1838–1845. https://ajindex.com/articles/610716

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Goeminne P, Dupont L. Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgrad Med J 2010; 86: 493-501
  2. Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, Wilson R. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009; 34: 843-849
  3. Finklea JD, Khan G, Thomas S, Song J, Myers D, Arroliga AC. Predictors of mortality in hospitalized patients with acute exacerbation of bronchiectasis. Respir Med 2010; 104: 816-821
  4. Tsang KW, Tipoe GL. Bronchiectasis: not an orphan disease in the East. Int J Tuberc Lung Dis 2004; 8: 691-702
  5. Habesoglu MA, Ugurlu AO, Eyuboglu FO. Clinical, radiologic, and functional evaluation of 304 patients with bronchiectasis. Ann Thorac Med 2011; 6: 131-136
  6. Habesoglu MA, Tercan F, Ozkan U, Fusun EO. Effect of radiological extent and severity of bronchiectasis on pulmonary function. Multidiscip Respir Med 2011; 6: 284-290
  7. Goeminne PC, Nawrot TS, Ruttens D, Seys S, Dupont LJ. Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir Med 2014; 108: 287-296
  8. Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, Poppelwell L, Sali W, Pesci A, Dupont LJ et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014; 189: 576- 585
  9. Poppelwell L, Chalmers JD. Defining severity in non-cystic fibrosis bronchiectasis. Expert Rev Respir Med 2014; 8: 249- 262
  10. Loebinger MR, Wilson R. Pharmacotherapy for bronchiectasis. Expert Opin Pharmacother 2007; 8: 3183-3193
  11. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, Fabbri LM, Johnston SL. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173: 1114- 1121
  12. Bedi P, Sidhu MK, Donaldson LS, Chalmers JD, Smith MP, Turnbull K, Pentland JL, Scott J, Hill AT. A prospective cohort study of the use of domiciliary intravenous antibiotics in bronchiectasis. NPJ Prim Care Respir Med 2014; 24: 14090
  13. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014; 189: 975-982
  14. Bhalla M, Turcios N, Aponte V, Jenkins M, Leitman BS, McCauley DI, Naidich DP. Cystic fibrosis: scoring system with thin-section CT. Radiology 1991; 179: 783-788. 15.